Sarcomas are rare cancers with high heterogeneity in terms of type, location, and treatment. The health-related quality of life (HRQoL) of sarcoma patients has rarely been investigated and is the subject of this analysis. Adult sarcoma patients and survivors were assessed between September 2017 and February 2019 in 39 study centers in Germany using standardized, validated questionnaires (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)). Associated factors were analyzed exploratively using multivariable linear regressions. Among 1113 patients, clinically important limitations and symptoms were most pronounced in emotional (63%, 95% CI 60–66%), physical (60%, 95% CI 57–62%), role functioning (51%, 95% CI 48–54%), and pain (56%, 95% CI 53–59%) and fatigue (51%, 95% CI 48–54%). HRQoL differed between tumor locations with lower extremities performing the worst and sarcoma types with bone sarcoma types being most affected. Additionally, female gender, higher age, lower socioeconomic status, recurrent disease, not being in retirement, comorbidities, and being in treatment were associated with lower HRQoL. Sarcoma patients are severely restricted in their HRQoL, especially in functioning scales. The heterogeneity of sarcomas with regard to type and location is reflected in HRQoL outcomes. During treatment and follow-up, close attention has to be paid to the reintegration of the patients into daily life as well as to their physical abilities and emotional distress.

<b><i>Background:</i></b> Data on institutional structures of sarcoma care in Germany are scarce. The utilization of an interdisciplinary tumor board (IDTB) is an essential part of modern cancer care. We investigated to which extent and when IDTB are used in sarcoma care. We hypothesized that IDTB before treatment initiation were used more often at certified cancer centers and at high-volume centers and that IDTB utilization increased over time. <b><i>Methods:</i></b> From 2017 to 2020 we conducted a prospective cohort study, undertaking major efforts to include the whole spectrum of sarcoma treatment facilities. To analyze potential predictors of IDTB utilization, we calculated multivariable logistic regressions. <b><i>Results:</i></b> Patients and survivors (<i>n</i> = 1,309) from 39 study centers (22 tertiary referral hospitals, 9 other hospitals, and 8 office-based practices) participated; 88.3% of the patients were discussed at some stage of their disease in an IDTB (56.1% before treatment, 78% after therapy, and 85.9% in metastatic disease). Hypotheses were confirmed regarding the utilization of IDTB in certified cancer centers (vs. all others: OR = 5.39; 95% CI 3.28–8.85) and the time of diagnosis (2018/2019 vs. until 2013: OR = 4.95; 95% CI 2.67–9.21). <b><i>Conclusion:</i></b><i></i>Our study adds to the evidence regarding the institutional structures of sarcoma care in Germany. Utilization of a tumor board before therapy seems to be in an implementation process that is making progress but is far from complete. Certification is a possible tool to accelerate this development.

Zusammenfassung Hintergrund Menschen mit Migrationshintergrund stellen eine heterogene Bevölkerungsgruppe dar mit einer Vielfalt an Ethnien, kulturellen und religiösen Ansichten und Erfahrungen. Die Diagnose und anschließende Behandlung einer Krebserkrankung gehen mit vielfältigen psychosozialen Belastungen einher. Daher war es Ziel dieser Studie, die aktuelle Perspektive von Ärzt/innen bezüglich Barrieren bei der psychoonkologischen Versorgung von MMH zu untersuchen sowie benötigte Hilfestellungen zu analysieren. Methode Es wurden bundesweit acht niedergelassene Ärzt/innen aus der hämatologisch-onkologischen Versorgung in qualitativen Einzelinterviews befragt. Die Interviews wurden digital aufgezeichnet und transkribiert. Die Auswertung erfolgte nach der inhaltlich strukturierenden Inhaltsanalyse mithilfe des Softwareprogramms MAXQDA 2020. Ergebnisse Identifiziert wurden 255 Codes in den Hauptkategorien „Definition Menschen mit Migrationshintergrund“, „Kommunikation“, „Kulturelle Unterschiede“, „Psychoonkologische Versorgung“, „Koordinierung & Vermittlung von psychoonkologischen Versorgungsangeboten“ sowie „Optimale psychoonkologische Versorgung“. Die Ergebnisse geben einen aktuellen Einblick in alltägliche und praxisrelevante Probleme, die sich in der transkulturellen Kommunikation, Barrieren hinsichtlich der Identifizierung von Bedürfnissen, in der psychoonkologischen Weiterversorgung oder auch während der Übersetzung durch Angehörige erkennen lassen. Diskussion Bereits die Identifizierung von Bedürfnissen während der ärztlichen Behandlung ist mit diversen Barrieren verbunden. Screening-Instrumente für Menschen mit Migrationshintergrund und Angehörige auf verschiedenen Sprachen und für unterschiedliche Kulturkreise könnten die Identifizierung unterstützen. Zudem müssten Netzwerke geschaffen werden, um Patient/innen anschließend auch psychoonkologisch versorgen zu können.

Background Sarcomas are rare cancers of high heterogeneity. Health-Related Quality of Life (HRQoL) has been shown to be a prognostic factor for survival in other cancer entities but it is unclear whether this applies to sarcoma patients. Patients and methods HRQoL was prospectively assessed in adult sarcoma patients from 2017 to 2020 in 39 German recruiting sites using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30). Vital status was ascertained over the course of 1 year. HRQoL domains were analysed by multivariable cox-regressions including clinical and socio-economic risk factors. Results Of 1102 patients, 126 (11.4%) died during follow-up. The hazard ratio (HR) for global health was 0.73 per 10-point increase (95% confidence interval (CI) 0.64–0.85). HR for the HRQoL-summary score was 0.74 (CI 0.64–0.85) and for physical functioning 0.82 (CI 0.74–0.89). There was also evidence that fatigue (HR 1.17, CI 1.10–1.25), appetite loss (HR 1.15, CI 1.09–1.21) and pain (HR 1.14, CI 1.08–1.20) are prognostic factors for survival. Conclusion Our study adds sarcoma-specific evidence to the existing data about cancer survival in general. Clinicians and care-givers should be aware of the relations between HRQoL and survival probability and include HRQoL in routine assessment.

No abstract